市場調查報告書

全球勃起功能障礙治療藥市場:產品,各地區(2018年∼2023年)

Global Erectile Dysfunction Drugs Market - Segmented by Product, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 704961
出版日期 內容資訊 英文 109 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球勃起功能障礙治療藥市場:產品,各地區(2018年∼2023年) Global Erectile Dysfunction Drugs Market - Segmented by Product, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年08月01日內容資訊: 英文 109 Pages
簡介

全球勃起功能障礙治療藥市場,預計從2018年到2023年的整個預測期內以約8%的年複合成長率發展。

本報告提供全球勃起功能障礙治療藥市場調查,市場概要,各產品、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題(DROC)

  • 市場成長要素
    • 心臟疾病和糖尿病的併發症
    • 由於持續抽煙造成的罹患率上升
    • 壓力及久坐的生活方式
  • 市場阻礙因素
    • 患者對治療的抗拒感
    • 服藥醫囑遵從性不良
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品
    • Viagra (sildenafil citrate)
    • Cialis (Tadalafil)
    • Levitra/Staxyn (vardenafil)
    • Stendra/Spedra (avanafil)
    • Zydena (udenafil)
    • Vitaros (Alprostadil Cream)
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cristalia Produtos Quimicos Farmaceuticos Ltd
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Meda Pharmaceuticals Inc.
  • Pfizer, Inc.
  • SK chemicals
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.

第10章 市場未來展望

目錄
Product Code: 62838

Erectile Dysfunction Drugs Market Overview

The erectile dysfunction (ED) drugs market is expected to grow, at a CAGR of approximately 8% during the forecast period. The market is dominated by North America owing to the access to an established healthcare infrastructure and growing R&D initiatives supporting the development of new drugs. North America was followed by Europe in 2017. Sedentary lifestyles, alcoholism and smoking greatly increases the risk of erectile dysfunction. Increasing adoption of these poor lifestyle choices will lead to the overall growth of the erectile dysfunction drugs market. Other factors driving the growth of the global erectile dysfunction drugs market are the increasing geriatric population and growing number of campaigns by government and Non-government organizations worldwide to make patients aware regarding ED.

Comorbidity between Erectile Dysfunction and Heart Diseases to Induce a Surge in the Erectile Dysfunction Drugs Market

The rise in number of ED cases can be co-related with the high growth of obesity, diabetes, and cardiovascular disorders. According to a study published on PMC by Arab Journal of Urology in 2013, ED could be an important marker for coronary artery disease (CAD). It has also been found that onset of ED preceded the onset of CAD in almost 2/3 of the cases. Hypertension is also another major illness linked to erectile dysfunction and as reported by CDC in 2018, the prevalence of hypertension has grown at a considerable rate, to approximately 65 million people suffering with the condition in US. The growing number of patients suffering from cardiovascular diseases is going to contribute to the rapidly growing pool of erectile dysfunction patients which in turn will lead to more patients seeking treatment hence boosting the Erectile Dysfunction Drugs Market during the forecast period.

Reluctance of Patients to Seek Treatment to Impede the growth of Erectile Dysfunction Drugs Market

Generally erectile dysfunction is considered as a physical problem, it is also due to poor psychological health. A large majority of the patients suffering from erectile dysfunction do not opt for treatment options. This is a direct result of the social stigma associated with having erectile dysfunction. According to Boston University School of Medicine, erectile dysfunction is a noteworthy disorder which affects a huge number of population. Restrictive attitudes of the population to open about their sexual health are often associated with strong religious beliefs, lack of education, work experience, and lower socioeconomic status. Due to these factors the patients suffering from erectile dysfunction to not seek treatment and hence can restrict the growth of the erectile dysfunction drugs market.

North America to Maintain Lead as the Largest Shareholder

The market dominated by North America owing to the access to an established healthcare infrastructure and growing R&D initiatives supporting the development of new drugs. North America was followed by Europe in 2017. The availability of various ED drugs through over the counter (OTC) and online channels is a key factor for dominance of these regions. The presence of online pharmacy stores is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase ED and other sexual wellness products.

Asia Pacific is estimated to witness relatively high growth owing to the rising geriatric population, changes in life style factors such as excessive alcohol consumption, smoking, and obesity. Increasing awareness about ED through various marketing campaigns and CME programs (Continuing Medical Education) is encouraging people to visit medical professionals and seek treatment for ED and associated problems. These developments are expected to positively reinforce growth prospects in the Asia Pacific region over the forecast period.

Key Developments in the Market:

May 2017: In India, Lupin Ltd. Launched Cialis an erectile dysfunction drug via a licensing agreement with Eli Lilly. In this alliance Eli Lilly will be responsible for manufacturing and importing the product.

Dec 2017: Pfizer, the manufacturer of Viagra (Sildenafil), settled trade disputes with generic manufacturer Teva Pharmaceutical Industries Ltd. This agreement allows Teva to start selling generic Viagra (sildenafil), which is expected to boost usage rates.

Major Players: APRICUS BIOSCIENCES INC., BAYER AG, CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTD, DONG-A ST CO.LTD, ELI LILLY AND COMPANY, MEDA PHARMACEUTICALS INC., PFIZER, INC.,SK CHEMICALS, TEVA PHARMACEUTICAL INDUSTRIES LTD, and VIVUS, INC. among others.

Reasons to Purchase the Report

Current and future Erectile Dysfunction Drugs Market outlook in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3-month analyst support, along with the market estimation sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Comorbidity between Erectile Dysfunction and Heart Diseases, and Diabetes
    • 6.1.2 Constantly Growing Tobacco Usage is driving the Incidence of ED
    • 6.1.3 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress
  • 6.2 Market Restraints
    • 6.2.1 Reluctance of Patients to Seek Treatment
    • 6.2.2 Poor Patient Adherence to ED Drugs
  • 6.3 Erectile Dysfunction Drugs Market Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By product
    • 7.1.1 Viagra (sildenafil citrate)
    • 7.1.2 Cialis (Tadalafil)
    • 7.1.3 Levitra/Staxyn (vardenafil)
    • 7.1.4 Stendra/Spedra (avanafil)
    • 7.1.5 Zydena (udenafil)
    • 7.1.6 Vitaros (Alprostadil Cream)
  • 7.2 By Geography
    • 7.2.1 North America
      • 7.2.1.1 US
      • 7.2.1.2 Canada
      • 7.2.1.3 Mexico
    • 7.2.2 Europe
      • 7.2.2.1 France
      • 7.2.2.2 Germany
      • 7.2.2.3 UK
      • 7.2.2.4 Italy
      • 7.2.2.5 Spain
      • 7.2.2.6 Rest of Europe
    • 7.2.3 Asia-Pacific
      • 7.2.3.1 India
      • 7.2.3.2 Australia & New Zealand
      • 7.2.3.3 South Korea
      • 7.2.3.4 Others
    • 7.2.4 Middle East & Africa
      • 7.2.4.1 GCC
      • 7.2.4.2 South Africa
      • 7.2.4.3 Rest of MEA
    • 7.2.5 South America
      • 7.2.5.1 Brazil
      • 7.2.5.2 Argentina
      • 7.2.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Apricus Biosciences, Inc.
  • 9.2 Bayer AG
  • 9.3 Cristalia Produtos Quimicos Farmaceuticos Ltd
  • 9.4 Dong-A ST Co., Ltd.
  • 9.5 Eli Lilly and Company
  • 9.6 Meda Pharmaceuticals Inc.
  • 9.7 Pfizer, Inc.
  • 9.8 SK chemicals
  • 9.9 Teva Pharmaceutical Industries Ltd.
  • 9.10 VIVUS, Inc.

List not Exhaustive

10. Future of the Market

Back to Top